Molecular and Clinical Characterization of CCT2 Expression and Prognosis via Large-Scale Transcriptome Profile of Breast Cancer

Qiang Liu†, Yihang Qi†, Xiangyi Kong†,‡, Xiangyu Wang†, Wenxiang Zhang†, Jie Zhai†, Yazhe Yang†, Yi Fang‡* and Jing Wang‡*

1 Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2 Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, United States

Molecular chaperones play important roles in regulating various cellular processes and malignant transformation. Expression of some subunits of molecular chaperone CCT/TRiC complex have been reported to be correlated with cancer development and patient survival. However, little is known about the expression and prognostic significance of Chaperonin Containing TCP1 Subunit 2 (CCT2). CCT2 is a gene encoding a molecular chaperone that is a member of the chaperonin containing TCP1 complex (CCT), also known as the TCP1 ring complex (TRiC). Through the Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases, we systematically reviewed a total of 2,994 cases with transcriptome data and analyzed the functional annotation of CCT2 by Gene ontology and KEGG analysis. Univariate and multivariate survival analysis were performed to investigate the prognostic value of CCT2 in breast cancer. We found CCT2 was significantly upregulated in various tumors. In breast cancer, CCT2 expression was significantly upregulated in HER2-positive (HER2+) group, and more malignant group. In addition, we investigated correlations between CCT2 and other CCT members. Interestingly, almost all CCTs expression were positively correlated with each other, but not CCT6B. Survival analysis suggested that CCT2 overexpression was independently associated with worse prognosis of patients with breast cancer, especially in luminal A subtype. In summary, our results revealed that CCT2 might be involved in regulating cell cycle pathway, and independently predicted worse prognosis in breast cancer patients. These findings may expand understanding of potential anti-CCT2 treatments. To our knowledge, this is the largest and most comprehensive study characterizing the expression pattern of CCT2 together with its prognostic values in breast cancer.

Keywords: breast cancer, CCT2 expression, prognostic, molecular chaperone, prognosis
INTRODUCTION

According to the “global cancer statistics” released by the World Health Organization (WHO) in 2015, approximately 1.15 million new cases of breast cancer are diagnosed every year and it accounts for 23% of all female malignancies; there are approximately 410,000 deaths every year, accounting for 14% of deaths due to cancer in women worldwide (1). Although breast cancer is one of the solid tumors of best prognosis and outcome, given that the figure differs significantly among different subtypes, there are still many problems to be solved urgently. With the beginning of the new era of precision medicine, we should give more emphasis on individualized and accurate diagnosis and treatment of breast cancer. Therefore, to seek for novel and promising biomarker for both diagnosis and treatment as well as effective therapeutic target is a major and pressing issue for us.

Although the hardened armors of cancer such as genomic instability, uncontrolled proliferation, metastasis, and so on make it a well-equipped army to fight against our various therapeutics (2, 3), it does have a soft spot: its dependency on major cellular processes like transcription, translation, splicing, protein degradation, and protein-folding (4). During this significant process, proteostasis network (PN), contributing a lot to keep proteome balanced, plays an important role in maintaining native function of proteins and ensuring the health of cell and organism. As the central components of the PN, one substance called chaperonin is a key player (5). There are various of proteins participating in proliferation, angiogenesis, survival, and migration, which are vitally essential for tumor formation, progression, and metastasis. To produce these proteins, cancer cells become more highly addicted to molecular chaperones since there are more imbalances caused by overexpression of oncogenes and chromosomal abnormalities (6).

Apart from the HSP90 inhibitors, which were found two decades ago and then abandoned due to incomplete inhibition of HSP90, dose-limited toxicity, and insufficient downregulation of client proteins (7, 8), there is another class of protein-folding complexes named chaperonins in recent years. As a large hetero-oligomeric ATP-dependent complex, this type II chaperonin named CCT is constructed by two stacked back-to-back rings, each creating a place called central chamber to sequester and fold substrate polypeptides that are newly synthesized or misfolded (9–12). CCT is composed of eight paralogous subunits: CCT1-8, also known as CCT α, β, γ, δ, ε, ζ, η, θ (13). Approximately 10% of newly synthesized proteins in eukaryotic cells are bound and folded under the assistance of CCT (14), and this figure is observed more in cancer cells. Moreover, the substrates in cancer cells consist of some oncogenic proteins as well as mediators such as STAT3, KRAS, and so on (15–18). Given the evidence that CCT facilitates neoplastic transformation, it is a newly emerging and promising substance that could probably serve as diagnostic marker as well as therapeutic target.

Considering the CCT was a complex that many previous studies focused on, without taking its structure constructed by eight different subunits into account, the importance of a single subunit, for example chaperonin containing TCP1 subunit 2 (CCT2 or CCTβ), was considerably undetermined.

According to several limited published studies, increased expression of CCT2 was observed in various tumor cell lines as compared to normal tissues, including liver, prostate, cholecyst, lung, colorectal, and breast cancers (15, 19–23). In terms of breast cancer, though several studies had illustrated the correspondence between CCT2 expression and the growth of breast cancer cells, there was no comprehensive and detailed conclusion based on clinical data towards different biological, clinical, and molecular characteristics of each distinct subtype (19, 24, 25). Therefore, many unknown factors regarding the expression and prognostic significance of CCT2 in breast cancer must be clarified.

In the present study, we assessed the CCT2 expression status and related biological process by characterizing transcriptome data across two comprehensive genomic databases including a total of 2,994 breast cancer samples. Further, we also explored relationships between CCTs gene family, and their prognostic value. To our best knowledge, this is the largest and most comprehensive study characterizing CCT2 expression in whole grade breast tumor masses.

METHODS AND MATERIALS

Data Acquisition

TCGA dataset on breast invasive carcinoma was downloaded and processed using GDCRNATools (access date: Feb 01, 2020) (26). Raw counts data normalized by TMM implemented in edgeR (27) was then transformed by voom in limma (28), and only genes with cpm > 1 in more than half of the samples were kept. Sieved TCGA breast cancer clinical data was kindly provided by Dr. Hai Hu and Dr. Jianfang Liu in Chan Soon-Shiong Institute of Molecular Medicine at Windber. HER2 status was recalled using DNA copy number for cases without an IHC or FISH status. Standardized survival data from TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR) (29) was utilized in this study. METABRIC dataset (30) on breast cancer (METABRIC, Nature 2012) acquired from cBioPortal (http://www.cbioportal.org/) were utilized for this study (access date: Feb 01, 2020). CCT2 expression data in GSE15852, GSE54002, GSE45827, and GSE42568 datasets were collected from GENT2 database (31) (http://gent2.appex.kr/gent2/), a newly updated platform for exploring gene expression patterns across tumor and normal tissues. Gene expression patterns of CCT2 across tumor and normal tissues were assessed using GENT2 database.

Kaplan-Meier Plotter Database Analysis

The Kaplan Meier plotter database (32) is capable to assess the effect of 54k genes on survival in 21 cancer types, breast cancer is the largest dataset in Kaplan-Meier plotter containing a total of 6,234 samples. The effect of CCT2 expression on survival together with hazard ratio (HR) with 95% confidence intervals and log-rank P-value in breast cancer was estimated by Kaplan-Meier plotter (http://kmplot.com/analysis).
FIGURE 1 | CCT2 expression levels in multiple types of human cancers. (A) CCT2 expression levels in all tumors and adjacent normal tissues across TCGA (*P < 0.05, **P < 0.01, ***P < 0.001). (B, C) Expression levels of CCT2 in 72-paired cancer and normal tissues derived from GPL570 and GPL96 microarray platform.
**RESULTS**

**Expression Pattern of CCT2 in Various Cancers**

To determine the mRNA levels of CCT2 in multiple human cancers, we analyzed expression of CCT2 using RNA-sequencing (RNA-seq) data derived from TCGA database. The expression of CCT2 in tumor and adjacent normal tissues across all tumors in TCGA were shown in Figure 1A. CCT2 expression was significantly higher in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), COAD (colon adenocarcinoma), ESCA (Esophageal carcinoma), HNSC (head and neck cancer), KIRP (Kidney renal papillary cell carcinoma), LIHC (liver hepatocellular carcinoma), LUAD (lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), PRAD (Prostate adenocarcinoma), READ (Rectum adenocarcinoma), STAD (stomach adenocarcinoma), and UCEC (Uterine Corpus Endometrial Carcinoma) when compared with adjacent normal tissues. However, CCT2 expression was significantly lower in only two types of cancers, that were, KICH (Kidney Chromophobe) and KIRC (Kidney renal clear cell carcinoma). To validate the expression pattern of CCT2 in various cancers, we further analyzed CCT2 expression in 72-paired tissues across more than 68,000 samples using GENT2 database. Both results from GPL570 and GPL96 microarray platforms revealed that global CCT2 expression was higher in tumor tissues compared with normal tissues (Figures 1B, C). CCT2 was higher in most of the tumor tissues when compared with normal tissues. Particularly, the global expression of CCT2 in breast cancer tissues was higher than normal tissues.

**Association Between CCT2 Expression and Clinical Characteristics of Breast Cancer Patients**

Expression of CCT2 were dichotomized into low- and high-expression groups using the median as a cut-off value. We analyzed the associations of CCT2 expression and clinical characteristics in both TCGA cohort (n = 1090) and METABRIC cohort (n = 1904), results can be found in Tables 1 and 2. We found both two cohorts showed that CCT2

---

**TABLE 1 | Clinicopathologic characteristics according to expression level of CCT2 mRNA in TCGA database.**

| Age (years) | Total (n = 1,090) | CCT2 high (n = 545) | CCT2 low (n = 545) | P-value |
|-------------|------------------|---------------------|--------------------|---------|
| <55         | 517 (47.4%)      | 256 (47.0%)         | 261 (47.9%)        | 0.808   |
| >=55        | 573 (54.6%)      | 289 (53.0%)         | 284 (52.1%)        |         |
| T stage     |                  |                     |                    |         |
| T1          | 279 (26.6%)      | 127 (23.3%)         | 152 (27.9%)        | 0.012   |
| T2          | 621 (57.9%)      | 338 (62.0%)         | 283 (53.6%)        |         |
| T3          | 137 (12.6%)      | 56 (10.3%)          | 81 (14.9%)         |         |
| T4          | 40 (3.7%)        | 23 (4.2%)           | 17 (3.1%)          |         |
| Unknown     | 3 (0.3%)         | 1 (0.2%)            | 2 (0.4%)           |         |
| N stage     |                  |                     |                    |         |
| N0          | 514 (47.2%)      | 247 (45.3%)         | 267 (49.0%)        | 0.007   |
| N1          | 360 (33.0%)      | 176 (32.3%)         | 184 (33.8%)        |         |
| N2          | 120 (11.0%)      | 76 (13.9%)          | 44 (8.1%)          |         |
| N3          | 76 (7.0%)        | 31 (5.7%)           | 45 (8.3%)          |         |
| Unknown     | 20 (1.8%)        | 15 (2.8%)           | 5 (0.9%)           |         |
| M stage     |                  |                     |                    |         |
| M0          | 907 (83.2%)      | 473 (86.8%)         | 434 (79.6%)        | 0.005   |
| M1          | 22 (2.0%)        | 10 (1.8%)           | 12 (2.2%)          |         |
| Unknown     | 161 (14.8%)      | 62 (11.4%)          | 99 (18.2%)         |         |
| AJCC stage  |                  |                     |                    |         |
| I           | 181 (16.6%)      | 83 (15.2%)          | 98 (18.0%)         | 0.429   |
| II          | 621 (57.0%)      | 308 (56.5%)         | 313 (57.4%)        |         |
| III         | 250 (22.9%)      | 134 (24.6%)         | 116 (21.3%)        |         |
| IV          | 20 (1.8%)        | 9 (1.7%)            | 11 (2.0%)          |         |
| Unknown     | 18 (1.7%)        | 11 (2.0%)           | 7 (1.3%)           |         |
| ER status   |                  |                     |                    |         |
| Negative    | 236 (21.7%)      | 120 (22.0%)         | 116 (21.3%)        | 0.154   |
| Positive    | 803 (73.7%)      | 393 (72.1%)         | 410 (75.2%)        |         |
| Unknown     | 51 (4.7%)        | 32 (5.9%)           | 19 (3.5%)          |         |
| PR status   |                  |                     |                    |         |
| Negative    | 343 (31.5%)      | 184 (33.8%)         | 159 (29.2%)        | 0.081   |
| Positive    | 694 (63.7%)      | 330 (60.6%)         | 364 (66.8%)        |         |
| Unknown     | 53 (4.9%)        | 31 (5.7%)           | 22 (4.0%)          |         |
| HER2 status |                  |                     |                    |         |
| Negative    | 895 (82.1%)      | 424 (77.8%)         | 471 (86.4%)        | <0.001  |
| Positive    | 169 (15.4%)      | 100 (18.3%)         | 68 (12.5%)         |         |
| Unknown     | 27 (2.5%)        | 21 (3.9%)           | 6 (1.1%)           |         |
We further explored the differences in CCT2 expression between different clinicopathologic groups. CCT2 expression is significantly higher in PR positive (PR+) group (p = 0.013) and HER2 negative (HER2−) group (p = 0.014) (Figures 2A, B), and CCT2 overexpression in HER2+ group was also validated in TCGA cohort, but not PR− group (Figures 2E, F). In METABRIC cohort, CCT2 expression was higher in basal, HER2-enriched, luminal B group when compared with normal-like group (Figure 2C). CCT2 overexpression was found to be significant in Grade 3 when compared with Grade 1 (P < 0.0001) (Figure 2D). In TCGA cohort, elevated expression of CCT2 was found in higher T stage, and more aggressive subtype. CCT2 expression was significantly higher in tumor tissues compared with normal tissues (P < 0.0001) (Figures 2G–I), and this result was further validated in four independent microarray datasets derived from GEO database (Figures 3A–D).

### Association of CCT2 Expression and Patient Survival in Breast Cancer

We explored the prognostic value of CCT2 expression using KM-plotter database containing a total of 6,243 breast cancer samples. Kaplan-Meier analysis revealed that higher CCT2 expression was associated with worse overall survival (OS), relapse-free survival (RFS), and distant metastasis-free (DMFS) but not postprogression survival (PPS) (Figures 4A–B, D–E). CCT2 higher expression significantly correlated with worse OS was further validated in independent METABRIC cohort and TCGA cohort (Figures 4C, F). Furthermore, we assessed the prognostic value of CCT2 expression in subtype level, we found that higher expression significantly predicts worse OS in luminal A group in both KMplotter database (P < 0.0001) and TCGA cohort (p < 0.0001) (Figures 5A, E, G), but not luminal B, HER2, and basal group (Figures 5B–D, F, H).

### Univariate and Multivariate Analyses

Expression level of CCT2 mRNA was a significant factor in univariate analysis of both TCGA (HR, 1.306; 95% CI, 1.037–1.644; p = 0.023) and METABRIC (HR, 1.18; 95% CI, 1.075–1.295; p < 0.001) datasets (Table 3). We also found CCT2 was an independent significant prognostic factor for breast cancer according to multivariate analysis of TCGA cohort after adjusting for age, AJCC stage, ER status, PR status, as well as HER2 status (Figure 6A). Interestingly, CCT2 expression was also an independent prognostic factor for breast cancer in multivariate analysis of METABRIC cohort after adjusting for age, AJCC stage, Grade, ER status, PR status, as well as HER2 status (Figure 6B).

### CCT2-Related Signaling Pathways Identified Using Functional Enrichment Analysis

To explore the potential functional role of CCT2, genes correlated with CCT2 expression (Pearson |R|>=0.4) were screened out (n = 140) (Table S1), these genes were further used to do functional enrichment analysis in R using cluster Profiler package (35). Interestingly, GO analysis revealed that these genes were mainly involved in protein folding and binding biological processes (Table S2). KEGG enrichment analysis revealed that these genes were significantly enriched in cell cycle, oocyte meiosis, progesterone-mediated oocyte maturation, and RNA transport as well as p53 signaling pathway (Figure 7).

### Correlations Between CCTs Gene Family and Prognostic Value

We calculated the correlations of CCTs with each other by analyzing their mRNA expressions in TCGA cohort. Interestingly, we found almost all CCT genes were significantly positively correlated with each other, including CCT1, CCT2, CCT3, CCT4, CCT5, CCT6A, and CCT7 as well as CCT8, but not CCT6B (Figure 8). Furthermore, we systematically assessed...
the prognostic value of CCTs gene family using univariate analyses in both TCGA and METABRIC cohort (Table 4). CCT4 expression in METABRIC dataset can’t be accessed thereby prognostic value in METABRIC cohort was unknown. In summary, only CCT2 and CCT5 were significantly correlated with OS in both two cohorts.

**DISCUSSION**

Our work revealed that CCT2 tends to be overexpressed in tumor tissues compared with normal tissues. Moreover, CCT2 was overexpressed in more malignant grades and molecular subtypes of breast cancer. Genes correlated with CCT2 expression were
FIGURE 4 | Kaplan-Meier survival curves comparing the high and low expression of CCT2 in breast cancer. (A, B, D, E) Survival analysis derived from KMplotter database, and overall survival (OS), relapse-free survival (RFS), postprogression survival (PPS), and distant metastasis-free (DMFS); Hazard ratio, HR. (C, F) Survival analysis of CCT2 expression using TCGA and METABRIC cohorts.

FIGURE 5 | Kaplan-Meier survival curves comparing the high and low expression of CCT2 in breast cancer molecular subtype. (A–D) Survival analysis of CCT2 in breast cancer molecular subtype using KMplotter database. (E–H) Survival analysis of CCT2 in TCGA.
### TABLE 3 | Univariable analyses using TCGA and METABRIC databases.

| Factors          | Univariable analysis (TCGA) | Factors          | Univariable analysis (METABRIC) |
|------------------|-----------------------------|------------------|----------------------------------|
|                  | HR (95% CI)                 | P                | HR (95% CI)                      | P                |
| Age              | 1.032 (1.020–1.045)         | <0.001           | Age                              | 1.036 (1.030–1.041) | <0.001 |
| AJCC stage       | 2.207 (1.764–2.762)         | <0.001           | AJCC stage                       | 1.813 (1.622–2.027) | <0.001 |
| ER               |                             |                  | ER                               | Reference         |                  |
| Positive         | Reference                   |                  | Positive                         | Reference         |                  |
| Negative         | 1.389 (0.964–2.003)         | 0.078            | Negative                         | 1.180 (1.024–1.358) | 0.022 |
| Unknown          | 2.746 (1.425–5.292)         | 0.003            | Unknown                          |                  |                  |
| PR               |                             |                  | PR                               | Reference         |                  |
| Positive         | Reference                   |                  | Positive                         | Reference         |                  |
| Negative         | 1.347 (0.961–1.888)         | 0.083            | Negative                         | 1.269 (1.128–1.429) | <0.001 |
| Unknown          | 2.332 (1.149–4.730)         | 0.019            | Unknown                          |                  |                  |
| HER2             |                             |                  | HER2                             | Reference         |                  |
| Positive         | Reference                   |                  | Positive                         | Reference         |                  |
| Negative         | 0.893 (0.566–1.409)         | 0.626            | Negative                         | 0.688 (0.578–0.818) | <0.001 |
| Unknown          | 2.332 (1.149–4.730)         | 0.019            | Unknown                          |                  |                  |
| CCT2             | 1.306 (1.037–1.644)         | 0.023            | CCT2                             | 1.180 (1.075–1.295) | <0.001 |
| Grade            | —                           |                  | Grade                            | 1.273 (1.156–1.403) | <0.001 |

**FIGURE 6** | Multivariate analysis of CCT2 expression adjusting for ER, PR, HER2, AJCC stage, age, and stage in TCGA cohorts (A) as well as METABRIC cohort (B). *P < 0.05, **P < 0.01, ***P < 0.001.
mainly enriched in cell cycle pathway and also P53 signaling pathway. To the clinical aspects, our results indicated CCT2 expression was independently associated with worse prognosis of patients with breast cancer, especially in luminal A subtype. Additionally, we also explored potential relationships between CCTs gene family and their prognostic role in breast cancer.

Many previous studies have focused on colorectal cancer, gallbladder cancer, liver cancer, prostate cancer, small cell lung cancer, and so on. For example, Park et al. found that the tissues of human colorectal cancer showed greater CCT2 expression than did the normal colon tissues, which indicated that higher CCT2 expression in tumor tissues from colorectal cancer patients reduced their survival rate. Besides, on the basis of the research conducted by Zou et al., in gallbladder cancer, the positive expression of PDIA3 and CCT2 was significantly associated with clinicopathological features of both squamous carcinoma/adenosquamous carcinoma and adenocarcinoma specimens, consisting of lymph node metastasis and high TNM stage (22). Though there were several valuable outcomes, much more work related to BLCA, ESCA, HNSC, STAD, UCEC, and renal tumors remains to be done, which will inevitably lead to a much more comprehensive understanding of the function of CCT2 in numerous cancers.

With regard to breast cancer, there were some published researches concerning CCT2 of high-quality. The first one was a study conducted by AH Charpentier et al. released in 2000, they illustrated that Pescadillo and chaperonin CCT2 were two presumptive autocrine/paracrine factors of potential function in the regulation of the growth of breast cancer cells, which were identified to be highly upregulated by E2 (17beta estradiol) (24). Besides, the research conducted by Stephen T. Guest et al. represented some unique new findings. They identified that CCT1 and CCT2 were necessary for growth/survival of breast cancer cells in vitro and were determinants of overall survival in breast cancer patients (19). Apart from that, another research conducted by Anne E. Showalter et al., published in this year also drew some conclusions. By depleting or overexpressing the subunit in breast cancer and breast epithelial cells, they found that increasing CCT2 in cells by 1.3–1.8-fold also increased other CCT subunits’ (CCT3, CCT4, and CCT5) levels, while silencing the expression of CCT2 by ~50% was able to cause other CCT subunits to reduce. Besides, their study also represented that cells expressing higher CCT2 were more invasive and showed a higher proliferative index, and depletion of CCT2 in a syngeneic murine model of triple negative breast cancer (TNBC) had a potential to prevent tumor growth (25). Though all these previous studies laid emphasis on the significance of CCT2 in breast cancer, what they focused on was only the growth and survival of breast cancer cells. There was no comprehensive and detailed conclusion towards different biological, clinical, and molecular characteristics of each distinct subtype. More importantly, transcriptome data we used in this study were derived from the top two biggest independent breast cancer databases, which enabled our outcomes much more overall and reliable.

As for other functions of CCT2, Park et al. found that reduction in CCT2 inhibited tumor induction by Gli-1, and ubiquitination-mediated Gli-1 degradation by β-TrCP occurred during incomplete folding of Gli-1 in hypoxia. CCT2 correlates with Gli-1 expression is an important determinant of survival in the colorectal cancer patients. Besides, based on the study conducted by Lu et al., they discovered that as an essential enzyme in de novo synthesis of purine, phosphoribosylformylglycinamidine synthase (PFAS) interacted with several proteins which played physiological roles in tumor development including CAD, CCT2, PRDX1, and PHGDH, and it was also able to deamidate PHGDH, and induce other posttranslational modification into CAD, CCT2, and PRDX1 (37). When it comes to other subunits of CCT complex, previous studies have reported some valuable points. In various cancers, the expression levels of different CCT subunits were upregulated in varying degrees: CCT3 in hepatocellular carcinoma (38), and CCT8 in hepatocellular carcinoma and glioblastoma (39, 40).
Based on study conducted by Hallal et al., extracellular vesicles from neurosurgical aspirates identified CCT6A as a potential glioblastoma biomarker with prognostic significance (41). Another group found that overexpression of CCT1 in yeast did not exert any effect on levels of assembled complex, but the CCT1 subunits which were remained soluble in the cytosol had inherent activity of protein-folding (42). In terms of CCT subunits acting as monomers, scientists found that CCT4 was able to produce a protrusion phenotype by interacting with microtubules and p150glued (43, 44). CCT5 and CCT8 could colocalize with actin fibers outside of the oligomer54, and CCT5 also played a key role in the transcriptional regulation of actin (45). Previous study also represented CCT5 had correspondence with breast cancer. Ooe A et al. discovered that CCT5, RGS3, and YKT6 mRNA expressions, which were upregulated in p53-mutated breast cancers, might be involved in resistance to docetaxel and clinically feasible in distinguishing the subset of breast cancer patients who may or may not be benefit from docetaxel therapy (46). Apart from that, CCT5 was identified to be closely related to lung cancer. Gao H et al. showed that CCT5 could induce an autoantibody response in non-small cell lung cancer (NSCLC) sera and showed higher expression in NSCLC tissues by Western blot and immunohistochemistry (47). Knockdown of CCT5, PIP4K2A, EXO1, CMBL, OPN3, and KMO, genes within 200 kb up/downstream of the three SNPs that were corresponded with small cell lung cancer (SCLC) overall survival (48). In addition, CCT5 also participated in replication of hepatitis C virus genome through interaction with the viral NS5B protein (49). However, the role of CCT in many diseases, including cancer, is far from fully characterized, needing much more researches and studies towards that.

Consistent to our results, some studies also reported the potential role of inhibiting cancer cell by targeting CCTs. For instance, Showalter Anne E et al., discovered one CCT inhibitor named CT20p, which had access to kill cancer cells in a CCT-dependent manner. In cancer cells where the CCT was inhibited, they were resistant to CT20p killing, while cells where the expression of CCT was increased were susceptible (15, 23). However, given the fact that the complexity of CCT and its multiple subunits, as well as the lack of a complete understanding of CCT substrate selectivity in vivo, there are inevitably some challenges that impede the development of feasible and effective therapeutics like CT20p (25). In summary, we discussed the role of CCT2 in tumors together with current researches regarding CCTs gene family. Future research focus on investigating the underlying molecular mechanisms of CCT2 in promoting cancer might yield novel insights for possible treatments by targeting CCT2.

### DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

### AUTHOR CONTRIBUTIONS

QL and YQ carried out the primary literature search. QL performed the data analysis. QL and YQ drafted the manuscript. QL, XW, WZ, JZ, YZY and XK performed the literature search and revised the manuscript. All authors contributed to the article and approved the submitted version.

### FUNDING

This paper was partially sponsored by grants from the National Natural Science Foundation of China, No. 81872160 (JW).

### ACKNOWLEDGMENTS

This manuscript has been released as a pre-print at Research Square (50). The authors thank Pro. Hai Hu and Dr. Jianfang Liu in Chan Soon-Shiong Institute of Molecular Medicine at Windber, for providing us high-quality TCGA breast cancer clinical data.

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.614497/full#supplementary-material

---

**TABLE 4 | Univariate analysis of CCTs in TCGA and METABRIC cohort.**

| Varname | Univariable analysis (TCGA) | | | Vari name | Univariable analysis (METABRIC) |
|---------|-----------------------------|---|---|-----------------------------|---|
|         | HR (95%CI) | P | |           | HR (95%CI) | P |
| CCT1    | 1.72 (1.34–2.11) | <0.001 | | CCT1    | 1.04 (0.96–1.14) | 0.344 |
| CCT2    | 1.31 (1.04–1.64) | 0.023 | | CCT2    | 1.18 (1.07–1.30) | 0.001 |
| CCT3    | 1.20 (0.92–1.57) | 0.173 | | CCT3    | 1.07 (0.95–1.20) | 0.293 |
| CCT4    | 1.53 (1.14–2.05) | 0.004 | | CCT4    | — | — |
| CCT5    | 1.30 (1.04–1.64) | 0.023 | | CCT5    | 1.27 (1.13–1.42) | <0.001 |
| CCT6A   | 1.15 (0.91–1.46) | 0.242 | | CCT6A   | 1.07 (0.95–1.21) | 0.257 |
| CCT6B   | 0.97 (0.8–1.18) | 0.776 | | CCT6B   | 0.77 (0.67–0.88) | <0.001 |
| CCT7    | 1.38 (0.99–1.92) | 0.055 | | CCT7    | 1.04 (0.96–1.13) | 0.327 |
| CCT8    | 1.37 (1.03–1.84) | 0.032 | | CCT8    | 0.92 (0.82–1.02) | 0.124 |
REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer J Clin (2015) 65:87–108. doi: 10.3322/ caac.21262

2. Douglas H, Weinberg RA. Hallmarks of Cancer: The Next Generation Cell (2000) 100:57–70. doi: 10.1016/S0092-8674(00)81683-9

3. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell (2000) 100:57–70. doi: 10.1016/S0092-8674(00)81683-9

4. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell (2007) 130:986–8. doi: 10.1016/j.cell.2007.09.007

5. Esfahani AH, Sverchkova A, Saez-Rodriguez J, Schuppert AA, Brehme M. A systematic atlas of chaperone deregulation topologies across the human cancer landscape. PLoS Comput Biol (2018) 14:e1005890. doi: 10.1371/journal.pcbi.1005890

6. Olszewski CM, Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol (2011) 490:71–92. doi: 10.1016/978-0-12-385114-7.00004-0

7. Neckers L, Workman P. Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? Clin Cancer Res (2012) 18:64–76. doi: 10.1158/1078-0432.CCR-11-1000

8. Yung A, Lee MJ, Lee S, Tomita Y, Rekhtman D, Moore B, et al. Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors. Methods Mol Biol (2018) 1709:423–41. doi: 10.1007/978-1-4939-7477-1_29

9. Bigotti MG, Clarke AR. Chaperonins: The hunt for the Group II mechanism. Cell Stress Chaperones (2009) 14:105–11. doi: 10.1007/s12192-008-0068-7

10. Yam AX, Yao Y, Lin H-TJ, Burlingame A, Gerstein M, Fridyman J. Define the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies. Nat Struct Mol Biol (2008) 15:1235–62. doi: 10.1038/nsmb.1515

11. Meyer AS, Gillespie JR, Walther D, Millet IS, Doniach S, Frydman J. Closing the Folding Chamber of the Eukaryotic Chaperonin Requires the Transition State of ATP Hydrolysis. Cell (2003) 113:381–391. doi: 10.1016/S0092-8674(03)00307-6

12. Halt F, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature (2011) 475:324–32. doi: 10.1038/nature10137

13. Joachimiak LA, Walzthoeni T, Liu CW, Aebersold R, Frydman J. The Structural Basis of Substrate Recognition by the Eukaryotic Chaperonin TRiC/CCT. Cell (2014) 159:1042–55. doi: 10.1016/j.cell.2014.10.042

14. Meyer AS, Gillespie JR, Walther D, Millet IS, Doniach S, Fridyman J. Closing the Folding Chamber of the Eukaryotic Chaperonin Requires the Transition State of ATP Hydrolysis. Cell (2003) 113:381–391. doi: 10.1016/S0092-8674(03)00307-6

15. Kasembeli M, Lau WC, Eckols TK, Frydman J, Aldaz CM. Effects of estrogen on global gene expression: Identification of novel targets of estrogen action. Cancer Res (2000) 60:5977–83.

16. Showalter AE, Martini AC, Nierenberg D, Hosang K, Fahmi NA, Gopalan P, et al. Investigating Chaperonin-Containing TCP-1 subunit 2 as an essential component of the chaperonin complex for tumorigenesis. Sci Rep (2020) 10:798. doi: 10.1038/s41598-020-75602-w

17. Li R, Qu H, Wang S, Wei J, Zhang L, Ma R, et al. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA, and mRNA data in GDC. Bioinformatics (2018) 34:2515–7. doi: 10.1093/bioinformatics/bty124

18. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinf (Oxford England) (2010) 26:139–40. doi: 10.1093/bioinformatics/btp616

19. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 43:47. doi: 10.1093/nar/gkv007

20. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell (2018) 173:400–11. doi: 10.1016/j.cell.2018.02.052

21. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda O, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 486:346–52. doi: 10.1038/nature10983

22. Park S-J, Yoon B-H, Kim S-K, Kim S-Y. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics (2019) 12:101. doi: 10.1186/s12920-019-0514-7

23. Nagr M, Länsö K, Menyhért O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep (2018) 8:9227. doi: 10.1038/s41598-018-27521-y

24. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res (2017) 77:e108–e10. doi: 10.1158/0008-5472.CAN-17-0307

25. Consortium GO. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res (2004) 32:2528–D61. doi: 10.1093/nig/200306

26. Kanehisa M. The KEGG database. In: Novartis Foundation Symposium. Novartis Found Symp: Wiley Online Library (2002). p. 91–100.

27. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics: J Integr Biol (2012) 16:284–7. doi: 10.1089/omi.2011.0118

28. Lu A, Disoma C, Zhou Y, Chen Z, Zhang L, Shen Y, et al. Protein interactome of the deamidase phosphoribosylformylglycinamidine synthetase (PFAS) by LC-MS/MS. Biochem Biophys Res Commun (2019) 513:746–52. doi: 10.1016/j.bbrc.2019.04.039

29. Qian EN, Han S-Y, Ding S-Z, Lv X. Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma. Cancer Cell Int (2016) 16:55. doi: 10.1186/s12935-016-0332-3

30. Qiu X, He X, Huang Q, Liu X, Sun G, Guo J, et al. Overexpression of CCT8 and its significance for tumor cell proliferation, migration and invasion in glioma. PloS One (2015) 211:717–25. doi: 10.1371/journal.pone.0041412

31. Huang X, Wang X, Cheng C, Cai J, He S, Wang H, et al. Chaperonin containing TCP1 subunit 8 (CCT8) is upregulated in hepatocellular carcinoma and promotes HCC proliferation. Apmis (2014) 122:1070–9. doi: 10.1111/apm.12258

32. Susannah H, Russell B, Wei H, Lee M, Toon C. Extracellular Vesicles from Neurosurgical Aspirates Identifies Chaperonin Containing TCP1 Subunit 6A (CCT6A) as a Potential Glioblastoma Biomarker with Prognostic Significance. Proteomics (2019) 19:1–2, e1800157. doi: 10.1002/pmc201800157

33. Tam S, Geller R, Spiess C, Fridyman J. The chaperonin TRC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol (2006) 8:1155–62. doi: 10.1038/ncll1477
43. Spiess M, Echbarthi M, Svanström A, Karlsson R, Grantham J. Overexpression Analysis of All Eight Subunits of the Molecular Chaperone CCT in Mammalian Cells Reveals a Novel Function for CCTdelta. *J Mol Biol* (2015) 427:2757–64. doi: 10.1016/j.jmb.2015.06.007

44. Meriem E, Josefine V, Julie G. Interactions between monomeric CCTδ and p150 Glued: a novel function for CCTδ at the cell periphery distinct from the protein folding activity of the molecular chaperone CCT. *Exp Cell Res* (2018) 376:137–49. doi: 10.1016/j.yexcr.2018.06.018

45. Elliott KL, Svanstrom A, Spiess M, Karlsson R, Grantham J. A novel function of the monomeric CCTδ subunit connects the serum response factor pathway to chaperone-mediated actin folding. *Mol Biol Cell* (2015) 26:2801–9. doi: 10.1091/mbc.E15-01-0048

46. Ooe A, Kato K, Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. *Breast Cancer Res Treat* (2007) 101:305–15. doi: 10.1007/s10549-006-9293-x

47. Gao H, Zheng M, Sun S, Wang H, Yue Z. Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer. *Oncotarget* (2017) 8:64170–9. doi: 10.18632/oncotarget.19369

48. Niu N, Schaid DJ, Abo RP, Kalari K, Fridley BL, Feng Q, et al. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. *BMC Cancer* (2012) 12:422. doi: 10.1186/1471-2407-12-422

49. Inoue Y, Aizaki H, Hara H, Matsuda M, Ando T, Shimoji T, et al. Chaperonin TRiC/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein. *Virology* (2011) 410:38–47. doi: 10.1016/j.virol.2010.10.026

50. Liu Q, Qi Y, Wang X, Kong X, Fang Y, Wang J. Molecular and clinical characterization of CCT2 expression at transcriptional level via 2994 samples of breast cancer. (2020). doi: 10.21203/rs.3.rs-44221/v1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Liu, Qi, Kong, Wang, Zhang, Zhai, Yang, Fang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*